SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is facing significant downward pressure following a disappointing quarterly earnings report, with the community actively debating whether the decline in core brand volume and margin compression signals a long-term shift or an overreaction. Investors are divided, with some liquidating positions due to lack of confidence in management and others viewing the sharp selloff as a discount opportunity for long-term growth potential.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant market volatility driven by a strong earnings beat, record revenue growth, and raised full-year guidance, which has intensified the conversation around a potential short squeeze given the stock's high short interest. While the community is actively debating the sustainability of the rally and the company's path to profitability, many are focused on the heavy trading volume and institutional accumulation as indicators that the stock could see further upside momentum.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is seeing high volatility and heavy trading volume as investors react to the expiration of IPO lock-up restrictions, with the community actively debating whether the resulting influx of shares will trigger a massive sell-off or be absorbed by institutional demand. While many bears anticipated a sharp decline, the stock has shown unexpected resilience, fueling intense discussions regarding potential short covering and the long-term outlook for the company.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is facing extreme bearish sentiment and high volatility as investors brace for upcoming earnings, with many questioning the company's long-term growth and leadership amid persistent sell-offs. While some market participants see a potential contrarian opportunity given the stock's depressed valuation and solid balance sheet, the community remains deeply divided, with many debating whether the stock is headed for a massive turnaround or a continued collapse toward single-digit levels.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending following a record-breaking second-quarter earnings report that saw revenue and gross margins significantly beat consensus expectations. The community is buzzing over management's confident outlook on the Amtagvi commercial ramp, rising demand for TIL therapy, and the potential for a short squeeze as investors digest strong operational efficiencies and positive signals regarding future pipeline developments.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending following a significant post-earnings selloff, as the stock faces intense volatility despite reporting strong year-over-year growth and resolving a prior SEC inquiry. The community remains deeply divided, with many investors debating whether the price drop represents a prime buying opportunity based on fundamentals or a warning sign of slowing momentum in the mobile advertising sector.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is experiencing extreme volatility as investors weigh strong demand for its public safety ecosystem and AI-driven growth against heavy insider selling and concerns regarding high valuation multiples. The community remains deeply divided, with some highlighting the stock's role as a long-term SaaS leader while others point to erratic price swings and dilution as signs of a potential ongoing sell-off.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as the stock surges to new 52-week highs, driven by investor confidence in its margin recovery and management's growth guidance. The community is actively debating whether to hold for long-term triple-digit potential or take profits after the recent vertical price appreciation, while some investors monitor the stock for a potential retest of breakout support levels.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and active community speculation ahead of its quarterly earnings, with investors weighing concerns over high valuation multiples against the company's aggressive expansion strategy and sustained consumer demand. While some are taking advantage of recent pullbacks to establish positions, others remain skeptical, citing the potential for margin pressure and a slowing consumer environment.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano is experiencing heightened community activity as investors weigh recent hard fork upgrades against broader concerns about the project's long-term utility and price stagnation. While some traders are actively accumulating during this period of low prices in anticipation of future recovery, others remain skeptical, citing concerns over leadership and the competitive landscape for layer-1 blockchains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.

What's Going On With Black Diamond Therapeutics Stock Tuesday?

Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.read more...

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.

Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday

Black Diamond Therapeutics (NASDAQ:BDTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-black-diamond-therapeutics-inc-stock...

HC Wainwright Issues Positive Forecast for BDTX Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright upped their Q1 2026 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Wednesday...

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

Investors need to pay close attention to BDTX stock based on the movements in the options market lately.

Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy

Jefferies Financial Group upgraded shares of Black Diamond Therapeutics to a "strong-buy" rating in a report on Thursday...

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Black Diamond Therapeutics Inc

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.10	--	--	N/A
Q2 '26	-$0.20	--	--	N/A
Q1 '26	-$0.18	-$0.16	13.25%	BEAT
Q4 '25	-$0.18	-$0.27	-50.93%	MISSED
Q3 '25	-$0.23	-$0.15	35.98%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '26

Historical Earnings